Positive News SentimentPositive NewsNASDAQ:NYXH Nyxoah (NYXH) Stock Price, News & Analysis $1.40 -0.07 (-4.76%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$1.40 +0.01 (+0.36%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock About Nyxoah Stock (NASDAQ:NYXH) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Nyxoah alerts:Sign Up Key Stats Today's Range$1.38▼$1.4350-Day Range$1.31▼$3.0252-Week Range$1.26▼$8.59Volume107,189 shsAverage Volume191,373 shsMarket Capitalization$54.27 millionP/E RatioN/ADividend YieldN/APrice Target$5.96Consensus RatingHold Company Overview Nyxoah SA, headquartered in Mont-Saint-Guibert, Belgium, is a medical technology company focused on neuromodulation therapies for sleep‐disordered breathing. Established in 2018, the company’s primary offering is the Genio® system, a minimally invasive bilateral hypoglossal nerve stimulator designed to treat moderate to severe obstructive sleep apnea (OSA). By electrically stimulating the genioglossus muscle, the device helps maintain airway patency during sleep, reducing apnea events and improving overall sleep quality. The Genio system comprises a small, implantable stimulator positioned submentally and an external activation unit worn by the patient. Prior to bedtime, users apply the activation patch, which wirelessly powers the implant and delivers timed electrical pulses to the tongue muscles. Following a CE mark in 2019, Nyxoah initiated commercial launches across Europe and select international markets. The company is actively pursuing additional regulatory clearances, including a premarket application with the U.S. Food and Drug Administration, and is conducting ongoing clinical studies to expand the system’s indications and validate long-term safety and efficacy. Building on its flagship product, Nyxoah continues to invest in research and development aimed at next-generation neuromodulation platforms for various sleep-related disorders. The company maintains a global footprint with commercial operations in Europe and a subsidiary in the United States, and collaborates with leading sleep centers to drive physician adoption and patient access. Nyxoah’s management team combines expertise in medical devices, sleep medicine, and implantable technologies to advance its mission of improving outcomes for patients suffering from obstructive sleep apnea.AI Generated. May Contain Errors. Read More Nyxoah Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks66th Percentile Overall ScoreNYXH MarketRank™: Nyxoah scored higher than 66% of companies evaluated by MarketBeat, and ranked 452nd out of 837 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingHold Consensus RatingNyxoah has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialNyxoah has a consensus price target of $5.96, representing about 325.9% upside from its current price of $1.40.Amount of Analyst CoverageNyxoah has only been the subject of 3 research reports in the past 90 days.Read more about Nyxoah's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Nyxoah are expected to grow in the coming year, from ($1.67) to ($1.26) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nyxoah is -0.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nyxoah is -0.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNyxoah has a P/B Ratio of 0.98. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Nyxoah's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.28% of the float of Nyxoah has been sold short.Short Interest Ratio / Days to CoverNyxoah has a short interest ratio ("days to cover") of 1.63, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Nyxoah has recently increased by 38.31%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNyxoah does not currently pay a dividend.Dividend GrowthNyxoah does not have a long track record of dividend growth. News and Social Media3.0 / 5News SentimentN/A News SentimentNyxoah has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.88 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Nyxoah this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for NYXH on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.6 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Nyxoah insiders have not sold or bought any company stock.Percentage Held by Insiders17.11% of the stock of Nyxoah is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsNyxoah has minimal institutional ownership at this time.Read more about Nyxoah's insider trading history. Receive NYXH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nyxoah and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NYXH Stock News HeadlinesNyxoah touts Genio US launch traction, reimbursement stability at investor dayJuly 11, 2026 | msn.comNyxoah SA (NYXH) Analyst/Investor Day TranscriptJuly 8, 2026 | seekingalpha.comIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially the reasons why we’re bombing the country.July 25 at 1:00 AM | Banyan Hill Publishing (Ad)Nyxoah (ENXTBR:NYXH) Stock Fair Value Moves Lower After Capital Raise And Analyst CautionJuly 8, 2026 | finance.yahoo.comNyxoah reports Q2 2026 preliminary revenue of €7.7MJuly 7, 2026 | msn.comNyxoah Announces Preliminary Results for the Second Quarter of 2026July 7, 2026 | globenewswire.comInformation on the total number of voting rights and sharesJune 30, 2026 | globenewswire.comPublication relating to transparency notificationsJune 29, 2026 | globenewswire.comSee More Headlines NYXH Stock Analysis - Frequently Asked Questions How have NYXH shares performed this year? Nyxoah's stock was trading at $4.60 at the start of the year. Since then, NYXH shares have decreased by 69.6% and is now trading at $1.40. How were Nyxoah's earnings last quarter? Nyxoah SA (NASDAQ:NYXH) posted its quarterly earnings data on Tuesday, May, 12th. The company reported ($0.43) earnings per share for the quarter, topping the consensus estimate of ($0.54) by $0.11. The company had revenue of $7.38 million for the quarter, compared to analysts' expectations of $7.05 million. Nyxoah had a negative trailing twelve-month return on equity of 163.73% and a negative net margin of 543.21%. Read the conference call transcript. When did Nyxoah IPO? Nyxoah (NYXH) raised $83 million in an initial public offering on Friday, July 2nd 2021. The company issued 2,760,000 shares at $30.00 per share. How do I buy shares of Nyxoah? Shares of NYXH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Nyxoah own? Based on aggregate information from My MarketBeat watchlists, some other companies that Nyxoah investors own include PayPal (PYPL), Confluent (CFLT), Datadog (DDOG), Baidu (BIDU), Arcadia Biosciences (RKDA), SEA (SE) and ZoomInfo Technologies (ZI). Company Calendar Last Earnings5/12/2026Today7/25/2026Next Earnings (Estimated)8/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (10m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 NYXH's financial health is in the Red zone, according to TradeSmith. NYXH has been in this zone for over 10 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MEDICAL INFO SYS Sub-IndustryMedical Equipment Current SymbolNASDAQ:NYXH CIK1857190 Webwww.nyxoah.com Phone321-022-2355Fax321-045-9075Employees110Year Founded2008Price Target and Rating Average Price Target for Nyxoah$5.96 High Price Target$11.00 Low Price Target$2.85 Potential Upside/Downside+325.9%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($2.48) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$101.92 million Net Margins-543.21% Pretax Margin-535.15% Return on Equity-163.73% Return on Assets-80.24% Debt Debt-to-Equity Ratio0.53 Current Ratio0.99 Quick Ratio0.88 Sales & Book Value Annual Sales$11.33 million Price / Sales4.79 Cash FlowN/A Price / Cash FlowN/A Book Value$1.43 per share Price / Book0.98Miscellaneous Outstanding Shares38,760,000Free Float32,129,000Market Cap$54.26 million OptionableNot Optionable Beta1.61 Social Links 10 Best Stocks to Own - Summer 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free Report This page (NASDAQ:NYXH) was last updated on 7/25/2026 by MarketBeat.com Staff. From Our PartnersLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredElon's new "super startup"Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...Banyan Hill Publishing | Sponsored“The unseen winner of the AI race” is not SpaceXMarc Chaikin - the analyst who called Nvidia before its historic run - says a tech firm labeled 'the unseen wi...Chaikin Analytics | SponsoredBlackRock, JPMorgan, and Goldman are all stock piling the same asset… are you?BlackRock, JPMorgan, Goldman Sachs, Fidelity, ARK Invest and Andreessen Horowitz are all buying the same asset...Awesomely | SponsoredThe cat is out the bagAlmost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered s...Porter & Company | SponsoredHe Called NVIDIA at $1.10 – Now He Says, “SELL”The analyst who called NVIDIA at $1.10 now says sell. According to Alexander Green, Chief Investment Strategis...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nyxoah SA Please log in to your account or sign up in order to add this asset to your watchlist. Share Nyxoah With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
